Comments on: Bone Marrow Transplants http://podcasts.mayoclinic.org/2008/05/16/bone-marrow-transplants/ Medical and Health Podcasts from Mayo Clinic Fri, 06 Nov 2009 18:23:23 +0000 http://wordpress.com/ hourly 1 By: Victor Okabe http://podcasts.mayoclinic.org/2008/05/16/bone-marrow-transplants/#comment-1314 Victor Okabe Fri, 26 Dec 2008 11:32:03 +0000 http://mcpodcasts.wordpress.com/?p=116#comment-1314 I am a 20 year old sickler and I have been thinking of a transplant for half a decade now. But every website I visited has a least one different thing to say. I am hence, asking for solid and total information on BMT, the success and survival tags and Nigeria's best hospitals for BMT. Will like to hear from you soon because I have celebrated less than 10 Xmasses without pains and 2008 wasn't pleasant. V C Okabe. I am a 20 year old sickler and I have been thinking of a transplant for half a decade now.
But every website I visited has a least one different thing to say.
I am hence, asking for solid and total information on BMT, the success and survival tags and Nigeria’s best hospitals for BMT.
Will like to hear from you soon because I have celebrated less than 10 Xmasses without pains and 2008 wasn’t pleasant.
V C Okabe.

]]> By: dr brenda http://podcasts.mayoclinic.org/2008/05/16/bone-marrow-transplants/#comment-232 dr brenda Sun, 24 Aug 2008 16:32:07 +0000 http://mcpodcasts.wordpress.com/?p=116#comment-232 i would like to know if ther are any good hospitals in Africa wher BMT can be done. i ve a sister that is a sickler.thanks i would like to know if ther are any good hospitals in Africa wher BMT can be done. i ve a sister that is a sickler.thanks

]]> By: Kristina Bruce RN http://podcasts.mayoclinic.org/2008/05/16/bone-marrow-transplants/#comment-46 Kristina Bruce RN Sat, 17 May 2008 14:25:22 +0000 http://mcpodcasts.wordpress.com/?p=116#comment-46 United Nations Economic Commission For Africa Book Of Abstracts Science With Africa Conference March 3-7, 2008 page 30 Evaluation of Niprisan (Herbal Medicine) for the Management of Sickle Cell Anaemia Charles Wambebe and Hadiza Khamofu, International Biomedical Research in Africa, Abuja, Nigeria, wambebe@yahoo.com, Joseph Okogun, Nathan Nasipuri and Karynius Gamaniel, National Institute for Pharmaceutical Research and Development, Abuja, Nigeria. About 70% of all sickle cell anemia (SCA) subjects reside in Africa, estimated at over 12 million. The prevalence of SCA is estimated at over 2% while infant mortality is about 8% and survival rate of SCA babies in rural areas by five years of age is about 20%. These statistics indicate that SCA is probably the most neglected (and sometimes forgotten by health authorities) serious public health disorder with serious mortality and morbidity rates in Africa. The objective was to undertake pre-clinical and clinical assessments of a herbal extract vis-à-vis management of sickle cell anemia using Good Laboratory Practice and Good Clinical Practice principles respectively. In Africa, there is no standard treatment for sickle cell anemia, only palliative management is generally available. In view of this situation, most SCA subjects use herbal medicines. NIPRISAN is a standardized extract from four medicinal/food plants: Piper guineenses seeds, Pterocarpus osun stem, Eugenia caryophyllum fruit and Sorghum bicolor leaves. Short term toxicity study indicated that NIPRISAN was safe in laboratory animals. Bio-activity guided fractionation show that vanillin and aromatic aldehydes may be the bioactive moieties. NIPRISAN reversed sickled red blood cells and protected them from being sickled when exposed to low oxygen tension. NIPRISAN dose- dependently delayed polymer formation of haemoglobin S. NIPRISAN induced 85% increased solubility of deoxy haemoglobin S. The in vivo efficacy study was undertaken at Children Hospital of Philadelphia, USA. Histological examination of lungs of control Tg transgenic mice carrying human sickle haemoglobin showed entrapment of massive numbers of sickled cells in alveolar capillaries. NIPRISAN significantly cleared the lungs of sickled cells. Furthermore, NIPRISAN induced profound effect on the survival time of Tg mice under hypoxic conditions (p<0.0001). The phase II clinical data indicated that all the subjects benefited from NIPRISAN with no serious adverse effect. About 80% of the subjects did not experience any crisis during the study (12 months). The subjects experienced significant reduction in hospital admission while attendance at school profoundly increased. Furthermore, there was no evidence of kidney or liver damage. NIPRISAN has been patented, licensed to an American company, registered and being manufactured at Abuja for global market. http://www.uneca.org/sciencewithafrica/content/swa_book_of_abstacts-en.pdf United Nations Economic Commission For Africa

Book Of Abstracts

Science With Africa Conference

March 3-7, 2008

page 30

Evaluation of Niprisan (Herbal Medicine) for the Management of Sickle Cell
Anaemia

Charles Wambebe and Hadiza Khamofu, International Biomedical Research in Africa, Abuja,
Nigeria, wambebe@yahoo.com, Joseph Okogun, Nathan Nasipuri and Karynius Gamaniel,
National Institute for Pharmaceutical Research and Development, Abuja, Nigeria.

About 70% of all sickle cell anemia (SCA) subjects reside in Africa, estimated at over 12 million. The prevalence of SCA is estimated at over 2% while infant mortality is about 8% and survival rate of SCA babies in rural areas by five years of age is about 20%. These statistics indicate that SCA is probably the most neglected (and sometimes forgotten by health authorities) serious public health disorder with serious mortality and morbidity rates in Africa. The objective was to undertake pre-clinical and clinical assessments of a herbal extract vis-à-vis management of sickle cell anemia using Good Laboratory Practice and Good Clinical Practice principles respectively. In Africa, there is no standard treatment for sickle cell anemia, only palliative management is generally available. In view of this situation, most
SCA subjects use herbal medicines. NIPRISAN is a standardized extract from four medicinal/food plants: Piper guineenses seeds, Pterocarpus osun stem, Eugenia caryophyllum fruit and Sorghum bicolor leaves. Short term toxicity study indicated that NIPRISAN was safe in laboratory animals. Bio-activity guided fractionation show that vanillin and aromatic aldehydes may be the bioactive moieties. NIPRISAN reversed sickled red blood cells and
protected them from being sickled when exposed to low oxygen tension. NIPRISAN dose- dependently delayed polymer formation of haemoglobin S. NIPRISAN induced 85% increased solubility of deoxy haemoglobin S. The in vivo efficacy study was undertaken at Children Hospital of Philadelphia, USA. Histological examination of lungs of control Tg transgenic mice carrying human sickle haemoglobin showed entrapment of massive numbers
of sickled cells in alveolar capillaries. NIPRISAN significantly cleared the lungs of sickled cells. Furthermore, NIPRISAN induced profound effect on the survival time of Tg mice under hypoxic conditions (p<0.0001). The phase II clinical data indicated that all the subjects benefited from NIPRISAN with no serious adverse effect. About 80% of the subjects did not experience any crisis during the study (12 months). The subjects experienced significant
reduction in hospital admission while attendance at school profoundly increased. Furthermore, there was no evidence of kidney or liver damage. NIPRISAN has been patented, licensed to an American company, registered and being manufactured at Abuja for
global market.

http://www.uneca.org/sciencewithafrica/content/swa_book_of_abstacts-en.pdf

]]>